Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. The user seeks input from medical professionals and scientists on these treatments.

A user shared their 5-month progress in treating hair loss using HIMs topical finasteride and minoxidil, micro-needling with a 1.5mm needle, and RU-58841. The post includes progress pictures showing improvement from a NW7 hair loss stage.

The conversation is about someone's three-year experience with irregular derma rolling, Minoxidil, and Redensyl for hair loss, hoping to thicken areas with fine hair.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

The conversation discusses using RU58841 with primobolan or masteron to protect hair while on steroids, alongside dutasteride. Users suggest caution with these compounds due to potential hair loss and discuss alternatives like nandrolone and EQ for better hair safety.

The user discusses using Minoxidil for hair loss and is considering RU58841 to reduce excessive oil production. They seek advice on RU58841's effectiveness in blocking sebum production.

RU58841 is used by some for hair loss, with mixed results; one user reported success with no side effects, while another experienced lung and heart issues. RU58841 is often sourced from third-party vendors and used alongside treatments like dutasteride and minoxidil.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

The conversation is about the progress of verteporfin in hair loss trials, with users expressing curiosity about its effectiveness and updates. Specific treatments mentioned include FUE (Follicular Unit Extraction) combined with verteporfin, with one reported case of donor area regrowth after a year, and three patients being monitored post-treatment by Dr. Bloxham with monthly updates on YouTube.

The conversation discusses hair loss treatment options, focusing on finasteride and its potential effects on gynecomastia. The user is considering finasteride while managing hormone levels with supplements like boron, vitamin D, zinc, magnesium, and P5P, and is advised to consult an endocrinologist for further evaluation.

User added RU58841 to their hair loss treatment and experienced quick results. Others also reported positive effects, but one user experienced chest pains as a side effect.

The conversation is about finding alfatradiol in the US for hair loss treatment. Specific treatments mentioned are Minoxidil, finasteride, and RU58841.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

A 21-year-old male experienced side effects from topical finasteride and is seeking alternative treatments to maintain hair until Breezula is available. He is considering using minoxidil, Nizoral, micro-needling, and vitamin D supplementation, and may try CB or RU58841 if necessary.

The conversation is about using RF microneedling with ExoHealer, along with finasteride and minoxidil, to improve hair thickness and reduce shedding. The user reports noticeable improvements in scalp texture and oiliness, with plans to consider stem cell treatments in the future.

The conversation is about a user's hair loss treatment routine, which includes RU58841 for 9 months and Dutasteride for 6 months, with other unspecified treatments considered extra. One user inquired about the source of RU58841.

RU58841 alone had mixed results; some users combined it with minoxidil. One user experienced side effects with finasteride and maintained with RU58841 and minoxidil, but noted possible chest pain.

A user is considering using topical finasteride, topical minoxidil, RU58841, and dermarolling twice a week to address hair loss after experiencing side effects with oral finasteride. They previously saw positive results with a topical spray containing finasteride, minoxidil, and tretinoin but discontinued use due to laziness.

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.

The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.

The user has tried many hair loss treatments including dutasteride, oral and topical minoxidil, topical finasteride, PRP, and microneedling without much success and is now using RU58841, seeing initial vellus hair growth but no further improvement after 5 months. They are inquiring about the effectiveness of RU58841 after 6-12 months of use.

A user ingested RU58841 orally and experienced severe heart and breathing issues, requiring emergency medical assistance. They concluded that MV supplements is a legitimate supplier but warned of the serious side effects.

The user experienced increased hair shedding after using RU58841, despite initial improvements in scalp condition and appearance. They are considering stopping RU58841 to see if shedding decreases.

The conversation is about purchasing RU58841 for hair loss treatment from Xian Lyphar BioTech. Users confirm the company is legitimate and the price is reasonable.

Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.

Rice bran is claimed to be as effective as Minoxidil in promoting hair growth. The conversation discusses using rice bran as an alternative treatment for hair loss.

miR-205, a tiny RNA, can stimulate hair growth by softening aging hair follicle stem cells in mice. Future tests aim to see if this can work in humans.

A user shared their positive experience with hair transplants by Dr. Craig Barton, having undergone two surgeries totaling 3,600 grafts for $12,000. They have been using finasteride and dutasteride for maintenance but stopped using minoxidil due to shedding issues.

The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly credits a person for the potential success of a treatment called GT20029.